| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Satraplatin (formerly JM-216; BMS-182751; JM216; BMS182751) is a DNA alkylating agent and the first oral platinum analog with antitumor activity. It is a platinum compound that is being studied as a potential treatment for patients with advanced prostate cancer who have not responded well to chemotherapy. The U.S. Food and Drug Administration has not yet given it their approval. Satraplatin, which was first reported in medical journals in 1993, is the first platinum-based chemotherapeutic medication that can be taken orally; the other platinum analogs, oxaliplatin, carboplatin, and isisplatin, need to be administered intravenously.
| ln Vitro |
|
|
|---|---|---|
| Cell Assay |
|
|
| References |
| Molecular Formula |
C10H22CL2N2O4PT
|
|---|---|
| Molecular Weight |
502.29256
|
| Exact Mass |
499.06
|
| Elemental Analysis |
C, 24.01; H, 4.43; Cl, 14.17; N, 5.60; O, 12.79; Pt, 38.99
|
| CAS # |
129580-63-8
|
| Appearance |
Solid powder
|
| SMILES |
CC(O[Pt]([NH2]C1CCCCC1)(Cl)(Cl)([NH3])OC(C)=O)=O
|
| InChi Key |
CKNPWBAXEKSCRG-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
|
| Chemical Name |
(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
|
| Synonyms |
Satraplatin; BMS182751; BMS-182751; BMS 182751; JM216; JM 216; JM-216
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF: ~10 mg/mL (~20 mM)
H2O: < 0.1 mg/mL Ethanol: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9909 mL | 9.9544 mL | 19.9088 mL | |
| 5 mM | 0.3982 mL | 1.9909 mL | 3.9818 mL | |
| 10 mM | 0.1991 mL | 0.9954 mL | 1.9909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03258320 | Recruiting | Drug: Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin |
Prostate Cancer Patients | Shanghai Jiao Tong University School of Medicine |
January 2015 | Phase 1 |
| NCT01289067 | Completed | Drug: Satraplatin | Prostate Cancer | William K. Oh | December 2010 | Phase 2 |
| NCT00370383 | Completed | Drug: Erlotinib Drug: Satraplatin |
Lung Cancer | Agennix | July 2006 | Phase 2 |
| NCT00499694 | Completed | Biological: bevacizumab Drug: satraplatin |
Prostate Cancer | Barbara Ann Karmanos Cancer Institute |
October 2007 | Not Applicable |
| NCT00473720 | Completed | Drug: Satraplatin Drug: Abraxane |
Advanced Cancers | Yale University | May 2007 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA